Table 4: Overview of the Treatment Effects Versus Placebo or Active Intervention by Study for PGADS Expressed as Difference in Change from Baseline

Placebo Naproxen 1000 Ibuprofen 2400 Diclofenac 150 Celecoxib 100 Celecoxib 200 Lumiracoxib 100 Lumiracoxib 200 Lumiracoxib 400 Etoricoxib 30 Etoricoxib 60
diff CFB* se diff CFB se diff CFB se diff CFB se diff CFB se diff CFB se diff CFB se diff CFB se diff CFB se diff CFB se
Schnitzer [33] Ref -15.3 3.65 -11.8 3.59 -11.7 3.67 -14 3.74
Smugar study 1 [26] Ref -14.5 2.21
Smugar study 2 [26] Ref -16.1 2.21
P007 [44] Ref -16.3 3.57 -25.3 3.54
P018 [np] Ref -18.6 3.29 -16.6 3.29
P019 [45] Ref -7.6 3.16 -9.3 3.16
P071 [43] Ref -11.4 2.66
P073 [47] Ref -8.1 2.65 -11.7 2.63
P076 [48] Ref -12.4 2.47 -16.4 2.48
P077 [48] Ref -15.9 2.55 -15.9 2.56
805-01*** [46] Ref 0.2 1.51

* Difference in change from baseline of intervention group versus placebo (or versus celecoxib in study 805-01). Negative effect indicates improvement favoring the active intervention reported in the table.
*** versus celecoxib 200.